Initial public offerings by biopharmaceutical companies in the US took a breather during the first two weeks of July as investors took time off around Independence Day, but drug developers – including Genmab AS with the biggest biopharma IPO so far this year – are jumping into the stock market once again.
The Danish company grossed $505.9m from the sale of 2.85m ordinary shares in the form of 28.5m American Depository Shares...